Sivik Global Healthcare LLC Invests $3.07 Million in Gilead Sciences, Inc. $GILD

Sivik Global Healthcare LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,069,000.

Other large investors also recently modified their holdings of the company. Ameriprise Financial Inc. boosted its holdings in shares of Gilead Sciences by 397.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after buying an additional 5,392,191 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after buying an additional 2,169,266 shares during the period. First Trust Advisors LP raised its stake in Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after buying an additional 1,874,508 shares during the period. Invesco Ltd. raised its stake in Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after buying an additional 1,618,453 shares during the period. Finally, Los Angeles Capital Management LLC raised its stake in Gilead Sciences by 46.7% during the 3rd quarter. Los Angeles Capital Management LLC now owns 3,845,379 shares of the biopharmaceutical company’s stock worth $426,837,000 after buying an additional 1,223,895 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Needham maintained a Buy on Gilead and set a $170 price target, citing the Tubulis acquisition as a clear enhancement to Gilead’s oncology risk/reward profile. Read More.
• Positive Sentiment: Market research firms (Leerink coverage cited in media pieces) reiterated Outperform/positive views after the Tubulis deal, highlighting the acquisition’s fit with Gilead’s strategy to bulk up oncology capabilities. Read More.
• Positive Sentiment: Independent press and company release confirm the terms: $3.15B upfront plus up to $1.85B in milestones, Tubulis to operate within Gilead post‑close, and the transaction expected to close in Q2 2026 — materially expanding Gilead’s ADC pipeline. Read More.
• Positive Sentiment: Seeking Alpha transcript and other coverage point to broader strategic M&A activity (Tubulis plus other targets mentioned), signaling management is prioritizing pipeline replenishment — investors interpret this as a growth/reshaping move. Read More.
• Neutral Sentiment: RBC bumped its price target to $123 while keeping a “sector‑perform” stance — a modest technical lift in coverage but the PT remains below current levels, reflecting mixed analyst conviction on near‑term upside. Read More.
• Neutral Sentiment: PRNewswire noted EQT Life Sciences’ exit via the sale to Gilead, which validates deal execution and provides third‑party confirmation of Tubulis’ strategic value — supportive but not a valuation catalyst by itself. Read More.
• Negative Sentiment: Some commentary frames the deal (and broader Q1 M&A push in pharma) as defensive — M&A “survival” moves can worry investors about near‑term dilution, integration risk, and the contingency nature of milestone payments. This caution is tempering upside for some traders. Read More.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $138.80 on Wednesday. The business’s fifty day simple moving average is $145.10 and its 200 day simple moving average is $130.01. The firm has a market capitalization of $172.28 billion, a P/E ratio of 20.50, a price-to-earnings-growth ratio of 1.83 and a beta of 0.39. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. Gilead Sciences’s dividend payout ratio is 48.45%.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the sale, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the insider owned 131,779 shares in the company, valued at $19,006,485.17. This trade represents a 2.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 299,280 shares of company stock valued at $42,820,550. 0.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft upped their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada upped their price target on Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Tuesday. Wells Fargo & Company upped their price target on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Scotiabank upped their price target on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Finally, Daiwa Securities Group upped their price target on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $157.81.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.